Literature DB >> 8010802

Reoperation for complications of the Angelchik antireflux prosthesis.

K C Stewart1, J D Urschel, R A Hallgren.   

Abstract

The Angelchik antireflux prosthesis is associated with complications that require reoperation in 5% to 15% of patients. To determine the morbidity and success of reoperation for these complications, we conducted a retrospective study of 15 patients. Time to reoperation ranged from 3 weeks to 113 months with a mean of 31 months. Indications for reoperation included dysphagia (8 patients), recurrent reflux (6 patients), and prosthesis migration (1 patient). Ten patients underwent prosthesis removal and fundoplication, 4 had prosthesis removal without fundoplication, and 1 patient had the prosthesis repositioned. Iatrogenic splenic injury occurred in 2 patients (13%); one splenectomy and one splenic repair were done. Four patients (27%) required intraoperative blood transfusion. There were no operative deaths. Removal of the prosthesis without fundoplication resulted in a significantly higher incidence of recurrent reflux (75%) than prosthesis removal and fundoplication (10%) (p < 0.04). Although reoperation for complications of the Angelchik antireflux prosthesis can be technically difficult, morbidity and mortality are acceptable. An antireflux procedure should be done at the time of prosthesis removal.

Entities:  

Mesh:

Year:  1994        PMID: 8010802     DOI: 10.1016/0003-4975(94)90122-8

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  2 in total

1.  Laparoscopic Removal of Angelchik Prosthesis Followed by Interval Sleeve Gastrectomy.

Authors:  Faryal G Afridi; Morgan Johnson; Kelsey A Musgrove; Salim Abunnaja; Lawrence E Tabone; David C Borgstrom; Nova Szoka
Journal:  Case Rep Surg       Date:  2019-05-21

2.  Systematic review of the introduction and evaluation of magnetic augmentation of the lower oesophageal sphincter for gastro-oesophageal reflux disease.

Authors:  E N Kirkham; B G Main; K J B Jones; J M Blazeby; N S Blencowe
Journal:  Br J Surg       Date:  2019-12-04       Impact factor: 6.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.